Evidence map›Paper›PMID 41992050›Full record

ReviewNature cancer2026

Advances in predicting T cell epitope recognition for cancer immunotherapy.

David Gfeller, Julien Racle, Alexandre Harari, Giancarlo Croce

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

David GfellerDepartment of Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland. david.gfeller@unil.ch.ORCID http://orcid.org/0000-0002-3952-0930
Julien RacleDepartment of Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-0100-0323
Alexandre HarariDepartment of Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-1055-2090
Giancarlo CroceDepartment of Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-0944-1884

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 320030-231333Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) CRSII5_193749
6 · The paper itself

Abstract

T cell recognition of malignant cells is central to cancer immunotherapy. This process is elicited by interactions between T cell receptors (TCRs) and antigenic peptides displayed on major histocompatibility complex molecules. Sequencing technologies enable characterization of genomic, transcriptomic and epigenetic alterations that can give rise to epitopes in cancer cells, alongside TCR repertoire profiling in T cells. An important challenge is to determine which peptides are recognized by T cells and which TCRs mediate this recognition. This Perspective highlights how technological and computational advances have improved epitope predictions, shed light on TCR-epitope recognition and could help leverage TCR repertoires for therapeutic innovations in cancer immunotherapy.

Indexed as

Epitopes, T-LymphocyteImmunotherapyNeoplasmsReceptors, Antigen, T-CellAnimalsAntigens, NeoplasmHumansImmunoinformaticsT-LymphocytesAntigens, NeoplasmEpitopes, T-LymphocyteReceptors, Antigen, T-Cell

Identifiers

PMID41992050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.